SCHEMBL6076025

SCHEMBL6076025

COc1ccc(Cl)cc1CS(=O)(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ADRB2 P07550 1/20 0.45
LMNA P02545 1/20 0.44
ALDH1A1 P00352 4/20 0.43
PKM P14618 2/20 0.43
WDR5 P61964 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
TSHR P16473 1/20 0.43
CYP2C19 P33261 1/20 0.43
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22191101 0.85 TRPV4 (0.53) TRPV4MEN1KMT2ACA1CA2
SCHEMBL6077099 0.83 CA1 (0.52) TRPV4MEN1KMT2ACA1CA2
SCHEMBL365584 0.78 LMNA (0.51) TRPV4MEN1KMT2ACA1CA2
SCHEMBL11433050 0.78 ALDH1A1 (0.54) MEN1KMT2ALMNAALDH1A1CYP1A2
SCHEMBL13321612 0.77 CYP3A4 (0.41) MEN1KMT2AL3MBTL1LMNAALDH1A1
SCHEMBL3028416 0.77 MEN1 (0.49) TRPV4MEN1KMT2ACA1CA2
SCHEMBL712489 0.77 MAPT (0.57) MEN1KMT2AL3MBTL1ADRB2LMNA
SCHEMBL7135010 0.77 MEN1 (0.54) MEN1KMT2AADRB2LMNAALDH1A1
SCHEMBL12370675 0.76 IDO1 (0.50) TRPV4MEN1KMT2AL3MBTL1ADRB2
SCHEMBL15415062 0.75 TRPV4 (0.50) TRPV4MEN1KMT2ACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098212-B2 Piperazine derivatives BLUMBERG LAURA C 2006-08-29 US disclosed
EP-1583533-A1 USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS Pfizer Products Inc. (US) 2005-10-12 EP disclosed
EP-1438298-A1 PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY Pfizer Products Inc. (US) 2004-07-21 EP disclosed
US-20040092529-A1 Methods of using piperazine derivatives PFIZER INC 2004-05-13 US disclosed
WO-2004039376-A1 USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS PFIZER PRODUCTS INC. (US) 2004-05-13 WO disclosed
US-20040034034-A1 Novel piperazine derivatives BLUMBERG LAURA C (US) 2004-02-19 US disclosed
WO-2003035627-A1 PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY PFIZER PRODUCTS INC. (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092529-A1 Methods of using piperazine derivatives CCR1, CCR3, CCR5 TRPV4 492/4885MEN1 4618/4885KMT2A 4125/4885
US-20040034034-A1 Novel piperazine derivatives CCR1, CCRL2, CCR5 TRPV4 398/4885MEN1 4737/4885KMT2A 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.